Skip to main content
TipRanks
Go Ultimate75% OFF

Renalytix (2O9) Q3 2024 Earnings Report

2 Followers

DE:2O9 Q3 2024 EPS Results

Actual EPS
-EUR 0.04
Consensus EPS
-EUR 0.04
Beat/Miss
Beat by +EUR 0.00
One Year Ago EPS
-EUR 0.06

DE:2O9 Q3 2024 Revenue Results

Actual Revenue
EUR 506.83K
Expected Revenue
EUR 991.41K
Beat/Miss
Missed by -EUR 484.58K
YoY Revenue Growth
-29.19%

Earnings Announcement Details

Quarter
Q3 2024
Date
05/15/2024
Time
Before Open
Conference Call
Wednesday, May 15, 2024
DE:2O9 Upcoming Earnings

Renalytix's next earnings date is estimated for December 8, 2026, based on past reporting schedules.

Q3 2024 Earnings Call Audio

DE:2O9 Q3 2024 Earnings Call
0:00 / 0:00

Q3 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2024 Earnings Call Summary

Q3 2024
Earnings Call Date:May 15, 2024|% Change Since:-77.90%|
Earnings Call Sentiment|Neutral

The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.

Company Guidance

During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.

  • Positive Medicare Coverage DevelopmentsMedicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.
  • Inclusion in International Clinical GuidelinesKidneyIntelX was included in the KDIGO international clinical guidelines for chronic kidney disease, marking a significant milestone for broader adoption.
  • Successful FundraisingCompleted common stock equity financing rounds in March and April, raising net proceeds of approximately $13.5 million, extending the financial runway.
  • FDA-Authorized Product LaunchLaunched the FDA-authorized KidneyIntelX.dkd product version, with commercial test orders now being received.
  • Cost Reduction AchievementsYear-over-year headcount reduction of 50% and overall operating expenses reduced by approximately 40%, aiming for further expense reductions.
  • Direct-to-Physician Sales GrowthAchieved a 33% increase in direct-to-primary-care test order rates quarter-over-quarter, indicating early growth trends.
  • Strategic Acquisition InterestReceived interest from multiple potential acquirers, with a competitive sale process anticipated.

DE:2O9 Earnings History

DE:2O9 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 08, 20262027 (Q1)―-―――
Oct 28, 20262026 (Q4)―-0.01――
Mar 26, 20262026 (Q2)―-0.02-0.0668.00% (+0.04)
Nov 26, 20252026 (Q1)―--0.04―
Nov 03, 20252025 (Q4)―--0.04―
Jun 17, 20252025 (Q3)―--0.1―
Mar 18, 20252025 (Q2)―-0.05-0.04-11.11% (-0.00)
Nov 20, 20242025 (Q1)―--0.05―
Oct 01, 20242024 (Q4)-0.02-0.04-0.0527.27% (+0.01)
May 15, 20242024 (Q3)-0.04-0.04-0.0642.86% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed